New combo tackles tough lymphoma
NCT ID NCT05322330
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new combination treatment for people with a type of blood cancer (B-cell non-Hodgkin's lymphoma) that did not respond to standard therapies. The treatment combined a drug (XPO-1 inhibitor) with specially engineered immune cells (CAR-T cells). The goal was to see if this combo could shrink tumors and control the disease. The study involved 20 adults and has been completed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Promising CAR-T therapy trial for lymphoma withdrawn before it began
- Double-Barreled attack: stem cell transplant plus CAR-T shows promise for Hard-to-Treat lymphoma
- Experimental combo therapy for tough lymphoma shows promise but trial halted early
- New hope for tough lymphoma: experimental drug JS203 enters human testing